Trials9 min read
EloraTZP Phase 2b: 23.3% Weight Loss in Type 2 Diabetes
Lilly's eloraTZP reported 23.3% weight loss vs 14.8% on tirzepatide alone in type 2 diabetes, but up to 27% stopped treatment. What Phase 2b showed.
Peptide Trials News
Phase readouts, head-to-head studies, pipeline data.
Daily Peptide News
New articles delivered to your inbox every morning. Free.
Trials News
Trials8 min read
Survodutide SYNCHRONIZE-2: 13.1% Loss in Type 2 Diabetes
Survodutide hit 13.1% weight loss in type 2 diabetes at 76 weeks in NEJM, but 18% quit over GI effects. How it compares with tirzepatide and semaglutide.
Trials7 min read
KAI-4729: New Triple Agonist Hits 16% in 12 Weeks
Kailera's KAI-4729, a retatrutide-style triple agonist, posted 16% weight loss and a 67% liver-fat drop in 12 weeks at EASD. What's actually sourceable.
Trials6 min read
ABBV-295: AbbVie Amylin Hits 9.8%, Eyes Monthly Dosing
AbbVie's amylin analog ABBV-295 reported up to 9.8% weight loss in 12 weeks, and a half-life that could support monthly dosing. What EASD 2026 showed.
Trials7 min read
Brenipatide: Lilly's Next GIP/GLP-1 Targets the Brain
Lilly's brenipatide enters Phase 3 for alcohol use disorder and depression — a weekly GIP/GLP-1 built for the brain. What GLP-1 buyers should watch.
Trials5 min read
Roche's Enicepatide: 15.5% Weight Loss in Diabetes Trial
Roche's dual GLP-1/GIP shot cut weight 15.5% and HbA1c 2.65 points in type 2 diabetes — 62% hit non-diabetic blood sugar. What it means for buyers.
Trials8 min read
EloraTZP: Eloralintide + Tirzepatide Hits 17% Loss
Lilly's eloraTZP — eloralintide plus tirzepatide — hit 17% weight loss in 16 weeks vs 10% on tirzepatide alone. Phase 2 data lands at EASD Sept 30.
Trials13 min read
NVG-291 Phase 3 Begins: Nerve Repair Peptide Data
NervGen's NVG-291 starts Phase 3 screening after 2.6x GRASSP gains in chronic paralysis. What the nerve peptide is — and what's sourceable instead.
Trials8 min read
ASC30 Oral GLP-1 Enters Phase 3: 7.7% Weight Loss
Ascletis dosed the first Phase 3 patient on ASC30 — and its oral GLP-1/GIP/amylin triple hit 15.2% in primates. What that means for buyers today.
Trials10 min read
GLP-1s and PMOS (PCOS): What the Trial Data Shows
A semaglutide analysis in PMOS — the condition formerly called PCOS — reported 52% lower testosterone and more regular cycles. What the data shows.
Trials9 min read
Ribupatide: 19.2% Weight Loss and No Way to Buy It
Kailera's ribupatide (KAI-9531) hit 19.2% weight loss in China's Phase 3 and is now in global trials. Why it isn't for sale — and what ships today.
Trials8 min read
Once-Yearly Semaglutide Implant: Phase 1 Dosing Done
Vivani dosed all 20 subjects in SLIM-1, the first human trial of a once-yearly semaglutide implant. Novo is evaluating it. What buyers can use now.
Trials5 min read
Retatrutide TRIUMPH-2/3: 22.6% Loss in Diabetes & CVD
Lilly's retatrutide met endpoints in two Phase 3 trials — up to 22.6% weight loss in obesity with diabetes and heart disease. What buyers should know.
Trials7 min read
Boehringer's BI 3034701: New Triple-Agonist in Phase 2
Boehringer's BI 3034701, a GLP-1/GIP/NPY2 triple agonist, entered Phase 2 for obesity. How it differs from retatrutide and what buyers can get now.
Trials5 min read
Bioglutide (NA-931) Phase 2: 13.8% Oral Weight Loss
The Phase 2 trial reported oral quadruple agonist NA-931 hit 13.8% weight loss with no muscle loss. How it stacks up to retatrutide.
Trials6 min read
KAI-7535: New Oral GLP-1 Pill Hits 11% Weight Loss
Kailera's KAI-7535 oral GLP-1 pill hit up to 11% weight loss in Phase 3 — but it's years from shelves. Here's what you can access today.
Trials6 min read
Retatrutide Cuts Knee OA Pain 73%, Sleep Apnea 61%
TRIUMPH-1's ADA 2026 baskets show retatrutide cut WOMAC knee pain 73% and sleep apnea events 61% — beyond weight loss. What it means for buyers.
Trials5 min read
Retatrutide TRANSCEND-T2D-1: 16% Loss in Diabetes
Retatrutide's first Phase 3 diabetes trial hit 1.9% A1C drops and 15.3% weight loss at 40 weeks — published in The Lancet. What it means for buyers.